CHARLES RIVER LABORATORIES INTERNATIONAL, INC.

News Charles River Laboratories International, Inc.

Stocks

CRL

US1598641074

Biotechnology & Medical Research

Market Closed - NYSE Other stock markets 04:00:02 2026-06-18 pm EDT			5-day change	1st Jan Change
185.00 ^USD	+1.46%		-1.34%	-7.26%

Jun. 18	Charles River Laboratories International, Inc. and Eli Lilly and Company Enter Collaboration to Optimize Ai/Ml Platform Through Nonclinical Testing Expertise	CI
Jun. 18	Rothschild & Co Redburn Adjusts Charles River Laboratories International PT to $241 From $230, Maintains Buy Rating	MT

All News

Mentions Relevance

Jun. 18	Charles River Joins Lilly TuneLab to Optimize AI/ML Platform through Nonclinical Testing Expertise	BU
Jun. 18	Rothschild & Co Redburn Adjusts Charles River Laboratories International PT to $241 From $230, Maintains Buy Rating	MT
Jun. 17	Charles River Laboratories Shares Rise After Morgan Stanley Upgrade	MT
Jun. 17	Morgan Stanley Upgrades Charles River Laboratories International to Overweight From Equal Weight, Adjusts PT to $220 From $185	MT
Jun. 05	Charles River Laboratories Has Potential to Outperform in 2H 2026, RBC Says	MT
Jun. 03	Charles River Laboratories International, Inc. Presents at Jefferies Global Healthcare Conference 2026, Jun-03-2026 09:55 AM
Jun. 02	Charles River Laboratories International, Inc. Presents at 46th Annual William Blair Growth Stock Conference, Jun-02-2026 10:00 AM
Jun. 01	Charles River Laboratories to Present at William Blair and Jefferies Conferences	BU
May. 13	Charles River Laboratories, Medipost Sign MoU on GMP-Compliant Testing	MT
May. 13	Charles River Laboratories and Medipost sign non-exclusive MoU to advance GMP testing solutions	RE
May. 13	Charles River Laboratories and MEDIPOST Sign Non-Exclusive MOU to Advance GMP Testing Solutions	BU
May. 11	Charles River Laboratories International, Inc. Approves Ratification of PricewaterhouseCoopers LLP as Independent Auditors	CI
May. 11	Charles River Laboratories International, Inc. Announces Board Elections	CI
May. 11	Charles River Laboratories International, Inc. Accelerates Digital Pathology with Ai-Powered End-To-End Workflow	CI
May. 11	Charles River Accelerates Digital Pathology with AI-Powered End-to-End Workflow	BU
May. 08	Charles River Laboratories International, Inc. Seeks M&A Opportunities	CI
May. 07	Charles River Laboratories International : Quarterly Report for Quarter Ending March 28, 2026 (Form 10-Q)	PU
May. 07	Tranche Update on Charles River Laboratories International, Inc.'s Equity Buyback Plan announced on November 5, 2025.	CI
May. 07	Charles River Laboratories International, Inc., Q1 2026 Earnings Call, May 07, 2026
May. 07	Charles River Laboratories International, Inc. Reports Earnings Results for the First Quarter Ended March 28, 2026	CI
May. 07	Charles River Laboratories Q1 Adjusted Earnings Decline, Revenue Rises; Maintains 2026 Earnings Guidance	MT
May. 07	(CRL) Charles River Laboratories International Expects 2026 Non-GAAP EPS Range $10.80 - $11.30, vs. FactSet Est of $11.08	MT
May. 07	Earnings Flash (CRL) Charles River Laboratories International, Inc. Posts Q1 Adjusted EPS $2.06 per Share, vs. FactSet Est of $1.94	MT
May. 07	Charles River beats quarterly estimates on steady demand for drug development services	RE
May. 07	Earnings Flash (CRL) Charles River Laboratories International, Inc. Reports Q1 Revenue $995.8M, vs. FactSet Est of $977.5M	MT